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Abstract: The venom of Apis mellifera (honey bee) has been reported to play a role in immunotherapy,
but existing evidence to support its immuno-modulatory claims is insufficient. Four fractions from
whole bee venom (BV) were separated using medium pressure liquid chromatography. Their ability
to induce the production of cytokines TNFα, IL-1β and IL-6 in phorbol-12-myristate-13-acetate
(PMA)-treated U937 cells was assessed. The levels of the three cytokines produced by stimulation
with the four fractions and crude BV without LPS were not significantly different from negative
control values. However, co-stimulation of the cells with LPS and Fraction 4 (F-4) induced a 1.6-fold
increase in TNF-α level (p < 0.05) compared to LPS alone. Likewise, LPS-induced IL-1β production
was significantly synergised in the presence of F-1 (nine-fold), F-2 (six-fold), F-3 (four-fold) and
F-4 (two-fold) fractions, but was only slightly enhanced with crude BV (1.5-fold) relative to LPS.
Furthermore, the LPS-stimulated production of IL-6 was not significantly increased in cells co-treated
with F-2 and F-3, but the organic fraction (F-4) showed an inhibitory effect (p < 0.05) on IL-6 production.
The latter was elucidated by NMR spectroscopy and found to contain(Z)-9-eicosen-1-ol. The effects
observed with the purified BV fractions were more marked than those obtained with the crude sample.
Keywords: bee venom; pro-inflammatory cytokines; LPS stimulation; U937 cells; PMA differentiated;
ELISA; (Z)-9-eicosen-1-ol; Apis mellifera
1. Introduction
Bee venom (BV) is mainly used as a defence tool by the honey bee, and its primary function is
to inflict pain on any intruders into the hive [1]. Despite its pain-causing effects, the main reported
human administration uses relate to pain relief in conditions, such as arthritis and rheumatism [2,3],
tendonitis, multiple sclerosis, wounds and gout [4–6]. The chemical composition of BV is complex,
but the primary ingredients are bioactive peptides, proteins and several other biomolecules [6–10].
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The principal component is a 26-amino acid haemolytic peptide, melittin, which accounts for about
50%–60% of the venom by dry weight and is responsible for most of the observed effects [9,11,12].
BV components have been reported to possess various and, sometimes, conflicting
immune-related effects. Available evidence suggests that apamin [13], histamine [14], mast cell
degranulating (MCD) peptide [15,16] and phospholipase A2 (PLA2) [17] significantly increase the
inflammatory response. The small neurotoxic peptide apamin (MW 2.0 kDa) is a Ca2+-activated
K+-channel blocker, which has been reported to increase murine T-cell proliferation [13]. However, it
has also been reported to inhibit histamine release in lung tissues, suggesting that it could decrease
allergic airway inflammation through mast cell stabilisation [18]. Park et al. (2004) also demonstrated
that histamine increased the production of IL-6 in nasal fibroblasts and induced nuclear factor kappa B
(NF-κB) [14], a transcriptional factor for many pro-inflammatory genes [19]. On the other hand, MCD
peptide was reported to inhibit histamine release from mast cells [15] by binding, in a dose-related
manner, to mast cell receptors, thereby partially inhibiting IgE binding to these receptors [20].
Similarly, PLA2 was shown to activate T-cells via its action on phospho-diacylglycerides to form small
neoantigenic factors in vivo, in a process dependent on antigen presentation by CD1a proteins [17].
Conversely, some components of BV have been reported to possess anti-inflammatory actions. For
instance, the basic polypeptide adolapin (MW 11.5 kDa) was reported to possess anti-inflammatory and
analgesic activities in carrageenan-, prostaglandin- and adjuvant-induced rat oedema and adjuvant
polyarthritis [21]. These effects were attributed to the inhibition of prostaglandin synthesis, via
cyclooxygenase inhibition, as well as through central mechanisms [21]. Adolapin was also shown
to inhibit the activity of BV PLA2 and human lipoxygenase from platelets and possessed antipyretic
effects [22].
Past reports on immuno-modulating effects of the main bee venom peptide melittin are rather
contradictory. For instance, whereas Bramwell et al. (2003) reported dose-dependent mucosal adjuvant
action of intranasal melittin co-administered with tetanus and diphtheria toxoids in mice [23], a
number of other studies have reported its “neutralising” effects on LPS in murine macrophage cell
lines [24,25]. The adjuvant effects of melittin were linked to its enhancement of vaccine absorption
across the mucosal lining, which led to higher antibody (IgG) titres than those of either component
alone [23]. On the other hand, its antagonistic effects on LPS were linked to inhibition of NF-κB
binding to DNA [24] and phosphorylation of IκB kinase [25], respectively. In addition, treatment of
LPS-stimulated BV2 immortalized murine microglial cells with BV or melittin, decreased the expression
of pro-inflammatory cytokines (IL-1β, IL-6 and TNF-α) and inhibited inducible nitric oxide synthase
(iNOS) production and nitric oxide (NO) expression, as was the expression of cyclooxygenase-2
(COX-2) and prostaglandin E2 (PGE2) production [26,27]. These anti-inflammatory effects were linked
mainly to the leucine zipper sequence in melittin, which contains two leucine residues, since Leu-Ala
substitution in this sequence progressively reduced this neutralising effect [27]. Jang et al. (2005)
also reported anti-inflammatory effects of BV in RAW 264.7 macrophages that were attributed to a
downregulation of iNOS, COX-2, NF-κB and mitogen-activated protein kinases (MAPKs) [28]. In
addition, Park et al. (2004) also reported that BV and melittin decreased carrageenan-induced oedema
and adjuvant-induced arthritis in rat models consistent with their inhibitory effects on LPS-induced
expression of COX-2, cytosolic PLA2 and iNOS and on the generation of PGE2 and NO [24]. BV and
melittin also prevented LPS-induced transcriptional and DNA binding activity of NF-κB via inhibition
of IκB release [2].
Since upregulation of most pro-inflammatory genes (e.g., cytokines and chemokines) relies on
activation of NF-κB [19], inactivation of the latter by BV or its components would be a key mechanism
for exerting anti-inflammatory effects [29]. However, in a previous study, no significant inactivation of
IL-1β-induced NF-κB was observed in fibroblast-like synoviocytes from rheumatoid arthritis patients,
as well as in dermal fibroblasts and red blood cells from healthy volunteers, after treatment with BV
and melittin [30]. In addition, there was no effect on the phosphorylation or degradation of IκB, and
even at high concentrations, BV and melittin had no effect on NF-κB-p50-DNA interactions. Instead,
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significant increases in mRNA levels of several pro-inflammatory genes (including COX-2, IL-1β,
TNF-α) and large quantities of oxygen radicals were observed following exposure to BV or melittin [30].
This suggested that melittin alone and BV as a whole are pro- rather than anti-inflammatory.
In the current study, the effects of BV and its fractions on the production of cytokines TNF-α, IL-1β
and IL-6 were investigated in PMA-treated U937 cells. The latter belong to a monocytic differentiation
lineage derived from malignant cells of a patient with generalised histiocytic lymphoma [31], and
their differentiation with PMA, a potent tumour promoting agent [32], is known to impart functional
properties typical of macrophages [32–34]. The presence of synergy between BV and LPS, a standard
antigen, in inducing the production of the pro-inflammatory mediators would suggest the potential
application of BV as a source of immuno-modulating agents for use as vaccine adjuvants.
2. Materials and Methods
2.1. Cell Culture
U937 cell cultures (obtained from ECACC, Porton Down, Salisbury, UK) were seeded at
3 ˆ 105 cells/mL in RPMI-1640 (Lonza, Verviers, Belgium) supplemented with 2 mM L-glutamine (Life
Tech, Paisley, UK), 100 IU/100 µg/mL penicillin/streptomycin (Life Tech, Paisley, UK) and 10% (v/v)
foetal bovine serum (FBS) (Sigma-Aldrich, Dorset, UK). Cells were subcultured every 2–4 days and
maintained at 37 ˝C in a humidified atmosphere of 5% CO2.
2.2. Test Sample Isolation, Preparation and Analysis
Crude BV (supplied lyophilized by Beesen Co. Ltd., Dae Jeon, Korea) was prepared for bioassay
by dissolving 10 mg in 1 mL of dimethyl sulphoxide (DMSO, Sigma-Aldrich) followed by filtration
through a 0.2-µm filter (Millex®, Sigma-Aldrich). The venom fractions F-1–F-4 were isolated from
800 mg of crude BV by reversed phase medium pressure liquid chromatography (MPLC) on a
Reveleris® iES flash chromatography system (Grace Davison Discovery Sciences, Carnforth, UK)
with dual UV (λ = 220/280 nm) and evaporative light scattering (ELSD) detection. The sample
was mixed with 3 g of Celite® before loading it into a dry-loading cartridge. The column used
was an Easyvarioflash D24 cartridge (VWR International, Lutterworth, UK) packed with ca. 13 g
of Polymeric Retain PEP for SPE (Thermo Scientific, Paisley, U.K.), as previously described [35].
Fraction F-1 was eluted with 100% water and F-4 with 100% acetonitrile (Sigma-Aldrich), both
solvents being of HPLC grade. Fractions F-2 and F-3 were eluted in water/acetonitrile mixtures
of 80/20% and 50/50%, respectively. The resulting purified fractions were freeze-dried and stored
at ´30 ˝C until required for the assay. Samples for bioassays were reconstituted at 10 mg/mL in
DMSO. Liquid chromatography-mass spectrometry (LC-MS) analysis of the freeze-dried fractions
was carried out. The samples were reconstituted in water (F-1, F-2 and F-3) or acetonitrile:water
(1:1) (F-4) to achieve concentrations of 0.1 mg/mL in each case, and 10-µL aliquots were injected into
a Finnigan Surveyor HPLC system interfaced to an Orbitrap Mass Spectrometer (Thermo Fisher
Scientific, Bremen, Germany). All of the samples were analysed using an ACE 3 C18 column
(150 ˆ 3.0 mm, 3 µm particle size) supplied by Hichrom Ltd. (Reading, UK). The mobile phase
consisted of 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B) at a flow rate of
0.3 mL/min. The gradient used for F-1 to F-3 was 20%–70% B from 0–10 min, 6 min hold at 70% B,
then return to 20% B over 4 min, followed by 5 min re-equilibration. In the case of F-4, an initial 5-min
isocratic profile at 50% B was followed by a 1-min ramp to 95% B, held there for 8 min, before a 1-min
return to 50% B and re-equilibration for 4 min. Full scan spectra were obtained within m/z 100–2000 in
the positive ESI mode for all samples, except F-4, which was detected in the m/z range 200–1200 in the
negative ESI mode. For MS/MS of F-4, collision-induced dissociation (CID) of the [M ´ H]´ parental
ion was carried out at a normalised collisional energy of 35.0 V, and the product ion scan was made in
the m/z rage of 200–700, also in the negative ESI mode. The spray needle voltages were set at 4.5 and
´3.5 kV in positive and negative ESI modes, respectively. The sheath and auxiliary gas flow rates were
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50 and 15 arbitrary units, respectively, while ion transfer capillary temperature was set at 275 ˝C. All
data were collected and processed using XCalibur software (version 2.1.0, Thermo Fisher Scientific,
Bremen, Germany).
2.3. Cytotoxicity Assay
U937 cells were seeded at 2.25 ˆ 104 cells/well in 96-well plates (Corning®, Sigma-Aldrich) and
incubated in the presence and absence of BV or its fractions at final concentrations ranging from
100 µg/mL–3 ng/mL (n = 3). Triton X at 1% (v/v) served as a positive control. The plate was then
incubated at 37 ˝C and 5% CO2 in a humidified atmosphere for 48 h. After incubation, Alamar® Blue
(AbD Serotec®, Kidlington, U.K.) was added at a final concentration of 10% in a total assay volume of
100 µL per well and the plate incubated for a further 6 h. Fluorescence readings of the plate were taken
using a Perkin Elmer Wallac Victor2 1420 Multilabel Counter (λEx/EM: 560/590 nm). All readings were
corrected for background by subtracting the mean fluorescence of the Triton X wells. Cell viability was
then calculated for each well as a percentage of fluorescence readings in the presence of test sample
relative to the mean value of the negative controls. The resulting data were analysed with GraphPad
Prism for Windows (version 4.03, GraphPad Software, San Diego, CA, USA, www.graphpad.com) to
obtain dose-response curves for each sample and their corresponding mean inhibitory concentration
(IC50) values.
2.4. Induction of Cell Differentiation
U937 cells were seeded at 4.5 ˆ 104 cells/well in a volume of 450 µL in 24-well tissue culture
plates (Corning®, Sigma-Aldrich) (n = 3) in media containing 60 ng/mL PMA (Sigma-Aldrich). A
control well containing cells in media without PMA was also included. The cells were then incubated
in a humidified atmosphere at 37 ˝C and 5% CO2 for 48 h. Micrographs of the cells were taken after
24 and 48 h for evidence of differentiation.
2.5. Stimulation of Cytokine Release
After 48 h of differentiation, the media were aspirated and replaced with fresh media, without
PMA, and the cells incubated for a further 24 h. At this point, samples of BV or fractions, with or
without Escherichia coli (E. coli) LPS (Sigma-Aldrich), were then added from a separate sample dilution
plate prepared using 10 mg/mL stock solutions (Table S1 in the Supplementary Materials). The final
concentrations of the samples on the cell culture plate were 100 µg/mL (F-1 and F-2), 12 µg/mL
(F-3 and BV) and 120 µg/mL (F-4), respectively. The final LPS concentration in the LPS-containing
samples was 1 µg/mL.
2.6. Assessment of Cytokine Release
Three ELISA kits from R&D Systems (Abingdon, U.K.) were used to assess the release of
interleukin (IL)-1β/IL-1F-2, IL-6 and tumour necrosis factor (TNF)-α from LPS-stimulated and
non-stimulated U937 cells. The ELISA assay was carried out according to the kit manufacturer’s
instructions, except that the colour substrate used (3,3’5,5’-tetramethylbenzidine, TMB) was from
Sigma-Aldrich (Dorset, U.K.) and came as ready for use. The reaction was stopped with 2 N sulphuric
acid (H2SO4) and the plate was read immediately at a 450-nm wavelength using a SpectraMax Pro 5
(Wokingham, U.K.) with wavelength correction by subtracting readings taken at 570 nm.
2.7. Data Analysis
Standard calibration curves were plotted by fitting the optical density data of TNF-α, IL-1β and
IL-6 to 4-parameter logistic (4-PL) regression curves (Table S2 and Figures S1–S9 in the Supplementary
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Materials). Each of these standards was prepared in duplicate at each of the concentrations in the
ranges recommended by the manufacturer. The 4-PL regression equation is given by:
y “ d` a´ d
1` ` xc ˘b (1)
where y is the response value (i.e., measured optical density), x is the concentration (in pg/mL) and a,
b, c and d are constants. The regression analysis also computes the R2 value, which gives an indication
of how best the fitted curve agrees with the data. From Equation (1), the unknown concentration, x, of
a sample of optical density, y, can be calculated according to:
x “ c
ˆ
a´ d
y´ d ´ 1
˙ 1
b
(2)
Using Equation (2), the concentrations of TNF-α, IL-1β and IL-6 induced by each of the samples
assayed (with and without LPS) were calculated and expressed as ratios of the mean cytokine level
induced by LPS (positive control), assayed in triplicate (n = 3). The resulting data were then analysed
with GraphPad Prism to obtain bar graphs whose statistical significances were tested at the 95%
confidence level (CI) relative to the mean positive control ratio of 1.0.
2.8. NMR Spectroscopy
NMR spectroscopy was carried out on 7.4 mg of BV fraction F-4 dissolved in 600 µL DMSO-d6.
NMR data were acquired with a Bruker AVANCE II+ NMR spectrometer (Bruker Biospin GmbH,
Rheinstetten, Germany) equipped with a 14.1 T UltrashieldTM superconducting magnet operating
at a 1H resonance frequency of 600.13 MHz under TopSpin (version 2.1, Bruker Biospin GmbH,
Rheinstetten, Germany) running in a Microsoft Windows environment. All data were acquired using
a BBO-z-atm probe head operating at ambient temperature (298 K) regulated by means of a BCU-05
chiller unit.
1D 1H-NMR spectra were acquired with 16 transients over a frequency width of 7.2 kHz
(12.0 ppm) centred at a frequency offset of 5.0 ppm into 32 K data points for an acquisition time
of 2.27 s using a 30-degree radio frequency (r.f.) pulse and a recycle delay of 2.0 s.
1D 13C-{1H} NMR spectra were acquired with 1024 transients over a frequency width of
33.33 kHz (220.8 ppm) centred at a frequency offset of 100.0 ppm into 32 K data points for an acquisition
time of 491.5 ms using a 30-degree r.f. pulse with continuous composite pulse decoupling applied at
the 1H resonance frequency and using a recycle delay of 0.7 s.
Complete details for all NMR experimental conditions can be found in the Supporting Information.
3. Results
3.1. Composition of Fractions 1–4 from MPLC
From LC-MS analysis, the fractions were revealed to contain mixed components in F-1 and F-2,
while F-3 and F-4 both contained largely single components. The major constituents of F-1 were
putatively identified to be histamine, proline, noradrenaline, 5-aminovaleric acid, cellobiose and
arginine (Figure S10). Fraction F-2 contained mainly PLA2, as well as varying amounts of apamin,
secapin and MCD peptide (Figure S11). On the other hand, melittin was the principal component
of F-3 (96% purity) (Figure S12), while the organic fraction, F-4, mainly contained a new compound
identified through NMR analysis as (Z)-9-eicosen-1-ol and trace levels of an unidentified phospholipid.
The LC-MS did not detect (Z)-9-eicosen-1-ol due to its absolute lack of ionisation in both positive and
negative ESI modes, but instead detected the trace phospholipid impurity, undetected by NMR at its
concentration in the fraction (Figure S13).
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3.2. Cytotoxicity of BV Fractions against U937 Cells
Cytotoxicity studies were carried out (n = 3) to obtain IC50 values (Figure 1). Samples F-1 and
F-2 gave IC50 of greater than 100 µg/mL. In contrast, F-3 gave the lowest IC50 value at 5.4 µg/mL
(or 1.9 µM). The IC50 value of F-4 was 68.8 µg/mL. Micrographs of the cells taken after 24 and 48 h
confirmed the assay results obtained with the Alamar® Blue assay (Figure 2). These micrographs also
revealed significant microscopic differences in the appearance of cells treated with F-3 and F-4 even in
wells where Alamar® Blue readings were comparable. Unlike the necrosis caused by melittin, which
revealed the cells to have burst to release their protoplasm, non-viable F-4-treated cells appeared to
have an intact cell outline, implying that the mechanism by which the lipid exerts its cytotoxic effect
on U937 cells may be different from that of melittin, which acts through cell lysis [36].
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Figure 2. Cytotoxic effects of bee venom fractions on U937 cells. Fractions F-1 and F-2 were
non-cytotoxic at the highest concentration of 100 µg/mL used, while F-3 was the most cytotoxic
on the cells, as necrotic effects were observed even at 10 µg/mL (IC50 5.4 µg/mL). On the other hand,
F-4 was cytotoxic above 30 µg/mL with an IC50 of 68.8 µg/mL (n = 3). (Magnification = ˆ100).
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3.3. Selection of BV and Fraction Concentrations for the Assay
ELISAs were carried out in order to determine the effect of the fractions on PMA-differentiated
cells with respect to the production of three inflammatory mediators TNF-α, IL-1β and IL-6. Since the
investigation of immuno-modulatory effects had to be conducted using concentrations of the fractions
where the cells remained viable, concentrations were selected for each fraction that were below their
respective IC50 values. Specifically, the highest final concentration of the fraction at which no toxicity
was observed on the cells was used. Thus, F-1 and F-2 were each assayed at 100 µg/mL, F-3 and BV at
3 µg/mL, while F-4 was assayed at 30 µg/mL (Table S3 in the Supplementary Materials). The mean
viability (n = 3) of the cells at the concentrations selected for each of the fractions used for the assay
were F-1 (93%), F-2 (94%) and F-3 and F-4 (90% each), respectively, relative to the media control.
3.4. Effect of PMA on the U937 Cells
After the cells had been incubated in the presence of PMA, they were observed microscopically
at 24 and 48 h for the presence of features that confirmed whether or not they had differentiated [37].
Micrographs were also taken of the treated cells and compared to those of U937 cells in control wells
(absence of PMA) on the same plate (Figure 3), which confirmed the morphological changes expected.
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significant changes in the levels of the cytokine (n = 3). 
Figure 3. Effect of phorbol-12-myristate-13-acetate (PMA) on U937 cells. PMA was added to the cells
at 60 ng/mL (n = 3). (Magnification = ˆ400).
3.5. Effect on TNF-α Production
The BV fractions on their own did not induce significant TNF-α production in PMA-differentiated
U937 cells relative to the negative control (culture media). However, when used in combination with
LPS, there was a noticeable enhancement (ratio >1.0) in the amount of TNF-α produced compared to
LPS alone. This was statistically significant (p < 0.05) only with F-4, which produced a 1.6-fold increase
in TNF-α release from the cells (Figure 4).
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Figure 4. Effect of bee venom and its fracti f TNF-α productio in PMA-differentiated U937 cells.
All five samples t t d produced slightly r background levels of TNF-α, but not sig ificantly
different rom t ose of the n gative control ( i ). The level of TNF-α was significantly higher in
fractions co-stimulated with F-4 and LPS co pared to LPS, but the other fractions did not show any
significant changes in the levels of the cytokine (n = 3).
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3.6. Effect on IL-1β Production
The enhancement of IL-1β/IL-1F2 by BV fractions in LPS co-stimulated U937 cells was much more
pronounced than that observed with TNF-α. Fractions F-2 and F-3 greatly enhanced IL-1β/IL-1F2
release in the cells by approximately nine- and six-fold, respectively. Additionally, F-1 (four-fold), F-4
(three-fold) and whole BV (two-fold) also enhanced the release of this cytokine with LPS co-stimulation,
although the increase obtained with BV was not statistically significant (Figure 5). As can be seen from
Figure 5, the fractions on their own did not induce any significant level of cytokine release.
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Figure 5. Effect of bee venom and its fractions of IL-1β/IL-1F2 production in PMA-differentiated U937 
cells. All five been venom (BV) fractions tested produced only background levels of IL-1β/IL-1F2 
when used alone. In the presence of LPS, there was significant synergy, especially with F-2 and F-3, 
which resulted in a nine- and six-fold increase in the production of the cytokine, respectively. 
Significant synergy was also observed with F-1 (four-fold) and F-4 (three-fold), but not with BV 
despite a two-fold increase in the latter (n = 3). 
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TNF-α and IL-1β, F-4 significantly decreased the amount of IL-6 released with LPS co-stimulation in 
the PMA-differentiated U937 cells by about 50% (Figure 6). 
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Figure 6. Effect of BV and its fractions with and without LPS on IL-6 production in PMA-differentiated 
U937 cells. The level of IL-6 produced by BV fractions alone was undetectable. However, in 
combination with LPS, Fractions F-1–F-3 and BV enhanced the level of cytokine produced by LPS 
though not significantly. Interestingly, F-4 significantly inhibited cytokine production by about 50% 
of the mean positive control (LPS) value (n = 3). 
Figure 5. Effect of bee v nom and its fractions f I - /IL-1F2 productio in PMA-differentiated U937
cells. All five been venom (BV) fractions tested produced only background levels of IL-1β/IL-1F2 when
used alo e. In the presence of LPS, there was significa t synergy, especially with F-2 and F-3, which
resulted in a nine- and six-fold increase in the production of the cytokine, respectively. Significant
synergy was also observed with F-1 (four-fold) and F-4 (three-fold), but not with BV despite a two-fold
increase in the latter (n = 3).
3.7. Effect on IL-6 Production
As with TNF-α a d IL-1β production, the amount of IL-6 produced by the cells in th presence
of BV fractions alone was undetectable (F-1–F-3) or not significantly differ nt from levels observed
in negative controls (F-4 and BV). Yet, when the same fr ctions were incub ted together with LPS,
the amount of IL-6 produced by the cells was raised, compared to that of stimulation with LPS
alone, by 20%, 40%, 30% and 30% with F-1, F-2, F-3 and BV, respectively; although these were not
significantly different from positive control values. Surprisingly, and contrary to observations with
TNF-α and IL-1β, F-4 significantly decreased the amount of IL-6 released with LPS co-stimulation in
the PMA-differentiated U937 cells by about 50% (Figure 6).
Vaccines 2016, 4, 11 8 of 15 
 
3.6. Effect on IL-1β Production 
T e enhancement f IL-1β/IL-1F2 by BV fractions in LPS c -stimulated U937 cells was much 
m re pronounced than that observed with TNF-α. Fractions F-2 and F-3 greatl  enhanced  
IL-1β/IL-1F2 release in t e cells by approximately nine- and six-fold, respectively. Additionally, F-1 
(four-fold), F-4 (three-fold) and whole BV (two-fold) als  enhanced the release of this cytoki e with 
LPS co-stimulation, although the increase obtained with BV was not statistically significant  
(Figure 5). As can be seen from Figure 5, the fractions on their own did not induce any significant 
level of cytokine release. 
F-
1
F-
2
F-
3
F-
4
B
V
F-
1
F-
2
F-
3
F-
4
B
V
0
2
4
6
8
10
12
14
Mean IL-1 produced as
(sample + LPS)/LPS ratio
(n = 3)
Sample only
Sample + LPS
*
*
*
*
* Signific nt synergistic effect (p < 0.05) at 95% CI
Ratio = 1.0
C
y
to
k
in
e
 p
ro
d
u
c
ti
o
n
 a
s
(S
a
m
p
le
 +
 L
P
S
)/
L
P
S
 r
a
ti
o
 
Figure 5. Effect of bee v nom a d its fractions of IL-1β/IL-1F2 production in PMA-differentiated U937 
cells. All five been venom (BV) fractions tested produced nly background levels of IL-1β/IL-1F2 
when used alone. In the presence of LPS, there was significant synergy, especially with F-2 and F-3, 
which resulted in a nine- and six-fold increase in the production of the cytokine, respectively. 
Significant synergy was also observed with F-1 (four-fold) and F-4 (three-fold), but not with BV 
despite a two-fold increase in the latter (n = 3). 
3.7. Effect on IL-6 Production 
As with TNF-α nd IL-1β production, the amou t of IL-6 produced by the cells in the presence 
of BV fractions alone was undetectable (F-1–F-3) or n t significantly different from levels observed 
in negative controls (F-4 and BV). Yet, when the same fractions were incubated together ith LPS, 
the amount of IL-6 produced by the cells was raised, compared to that of stimulation with LPS alone, 
by 20%, 40%, 30% and 30% with F-1, F-2, F-3 and BV, respectively; alt ough these were ot 
significantly different from positive control values. Surprisingly, and contrary to observations with 
TNF-α and IL-1β, F-4 significantly decreased the amount of IL-6 released with LPS co-stimulation in 
the PMA-differentiated U937 cells by about 50  (Figure 6). 
F-
1
F-
2
F-
3
F-
4
B
V
F-
1
F-
2
F-
3
F-
4
B
V
0.0
0.5
1.0
1.5
2.0 Mean IL-6 produced as
(sample + LPS)/LPS ratio
(n = 3)

 Significa t antagonistic effect (p < 0.05) at 95% CI
Sample only Sample + LPS
Ratio = 1.0
C
y
to
k
in
e
 p
ro
d
u
c
ti
o
n
 a
s
(S
a
m
p
le
 +
 L
P
S
)/
L
P
S
 r
a
ti
o
 
Figure 6. Effect of BV and its fractions with  without LPS on IL-6 production in PMA-diff rentiated 
U937 cells. The level of IL-6 produced by BV fractions alone was undetectable. However, in 
combination with LPS, F actions F-1–F-3 and BV enhanced the level of cytokine produced by LPS 
though not significantly. Interestingly, F-4 significantly inhibited cytokine production by about 50% 
of the mean positive control (LPS) value (n = 3). 
Figure 6. Effect of BV and its fractions wit ithout LPS on IL-6 production in PMA- ifferentiated
U937 cells. The level of IL-6 produced b BV fractions alone was undetectable. However, in combination
with LPS, Fractions F-1–F-3 and BV enhanced the level of cytokine produced by LPS though not
significantly. Interestingly, F-4 significantly inhibited cytokine production by about 50% of the mean
positive control (LPS) value (n = 3).
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3.8. Identification of Active Compound in BV Fraction F-4
Given its unusual effect on TNF-α and IL-6 release in PMA-differentiated U937 cells, we sought
to identify the component present in F-4 by NMR spectroscopy. The one-dimensional (1D) 1H-NMR
spectrum of F-4 (acquired at 298 K in DMSO-d6; Figure S14) gave 10 distinguishable signals with
chemical shifts and integrals as detailed in Table 1. Signal A, which corresponded to a 1H chemical
shift associated with a proton attached to an sp2-hybridized carbon centre (alkene), integrated to two
proton equivalents. Multiplicity-edited 2D [1H, 13C] HSQC-NMR data revealed that the signal was
associated with a methine (CH) group, allowing the conclusion to be drawn that the molecule was
likely to be a structure with close to two-fold symmetry about a double bond. The signal envelope
designated H integrated to twenty two proton equivalents and suggested the presence of long chains
of methylene groups typical of a lipid.
Table 1. Data arising from the 1D 1H-NMR spectrum of the lipid component. Reference to the “link
to 13C” arises from analysis of the 2D [1H, 13C] HSQC-NMR spectrum that reveals 1JHC correlations
where labels a–q correspond to the 13C resonances shown in (Figure S12).
Label δ (ppm) Integral Type Multiplicity Link to 13C Proposal
A 5.32 2 Alkene CH Second order a SymmetricAlkene
B 4.30 1 -OH t - -CH2-OH
C 3.36 2 -CH2- dt b
D 3.32 1.7 H2O s -
Water in
DMSO
E 1.98 4 -CH2- q m
F 1.39 2 -CH2- pentet c
G 1.29 4 -CH2- q f
H 1.24 22 -CH2- - d,e,g,h,i,j,k,l,n,o
I 0.85 3 -CH3 t p -CH2-CH3
To establish how many types of carbon centres existed within the molecule, 13C-{1H} NMR data
(Figure S15) were examined. The data gave rise to 16 NMR signals corresponding to sixteen different
types of 13C environments. Many of these showed similar chemical shifts (signals e–l). Additionally
the intensities revealed that a number of carbon centres (a, f, l, m) were twice as abundant, resulting
from symmetry within the structure. It was clear in particular from these data that the carbon signal
(a) was due to two alkene carbons with identical chemical shifts, confirming the expectation that the
structure would be roughly symmetrical about a central double bond, the symmetry of which would
remain largely unaffected by remote tail groups.
2D [1H, 13C] HSQC-NMR data (Figure S16) at both low and high resolution allowed the types of
carbon to be distinguished for every centre, as well as editing the data to reveal protons that were not
attached to carbon. As well as enabling the identification of H/C correlations within each magnetic
environment, these data also made it possible to confirm the number of protons associated with the
lipid chain. These data also revealed that protons giving rise to Resonances B and D were not attached
to carbon. By analogy with literature examples, it was clear that Resonance D was associated with
water in DMSO and could therefore be discounted from the analysis. A summary of the 13C-NMR
data are shown in Table 2. These data are summarized to provide a molecular formula of C20H40O,
yielding a molecular weight (MW) = 296. Integration of the 1H-NMR spectrum is consistent with this
formula and the number of protons “counted” using the 2D [1H, 13C] HSQC-NMR data.
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Table 2. Summary of 13C-NMR data for the lipid molecule as revealed by 1D 13C-{1H} and 2D [1H, 13C]
HSQC-NMR data.
Label δ (ppm) No. of Carbons Type Link to 1H
a 130.09 2 CH A
b 61.18 1 CH2 C
c 33.03 1 CH2 F
d 31.76 1 CH2 H
e 29.58 1 CH2 H
f 29.56 2 CH2 G
g 29.50 1 CH2 H
h 29.45 1 CH2 H
i 29.35 1 CH2 H
j 29.31 1 CH2 H
k 29.17 1 CH2 H
l 29.06 2 CH2 H
m 27.03 2 CH2 E
n 25.99 1 CH2 H
o 22.57 1 CH2 H
p 14.40 1 CH3 I
Analysis of the remaining 2D [1H, 1H] COSY and TOCSY and 2D [1H, 13C] HSQC and
HMBC-NMR data (Figures S17–S19) is summarized in Table S7 and Table S8, respectively, in the
Supplementary Materials. The triplet character of 1H Resonance B and its correlation with Resonance
C by COSY and TOCSY indicated that the hydroxyl group was a terminal –OH attached to a methylene,
whose protons gave rise to Resonance C. The triplet character of proton Signal I similarly enabled the
identity of this resonance to be associated with a terminal methyl group. Correlations were traced
as far as possible from both the terminal positions and the alkene proton resonances (A) until these
assignment pathways merged at Resonance H. 2D [1H, 13C] HMBC-NMR data were used to establish
longer range H/C correlations to reinforce the assignments, which remaining incomplete owing to the
degeneracy at Signal H.
Following identification of coupling partners and piecing the structural evidence together, the
proton and carbon assignments were allocated to a basic structure, as shown (Figure S20). It was not
clear from the NMR data whether the double bond would be at the 9- or 10-position (shown in the
10-position in Figure S20). Neither was it clear from the data whether the double bond was of E or Z
configuration. For this reason, simulations of the data were carried out based on both E and Z isomers
of 9- and 10-eicosen-1-ol in order to throw some light on the conformation. Particular attention was
paid to the appearance of proton Resonances A and E in these simulations, which would reflect directly
on the conformation about the centralised double bond. The results of these simulations with their
equivalent experimental counterparts are shown in Figure S21.
On balance, these data suggest a greater likelihood of the lipid existing in the (Z)-configuration,
as shown in Figure S22. The position of the double bond is not revealed through these simulations or
by experiment. Comparison with information provided directly through Beesen Co. Ltd., suppliers of
the venom, suggests that the material and data are consistent with (Z)-eicos-9-en-1-ol.
3.9. Identification of Minor Component in F-4
Fraction F-4 was found to contain trace levels of an unidentified minor component with the
[M ´ H]´ elemental composition of C43H70O11P (0.0783 ppm mass tolerance) and MW 794.47.
Collisional induced dissociation (CID) of the parental ion (m/z 793.46) at a normalised collisional
energy (NCE) of 35.0 produced two daughter ions, one with m/z 493.2574 (C23H42O9P, 2.685 ppm
mass tolerance, 40%), possibly suggesting a loss of eicosapentenoic acid (MW 302), and the other with
m/z 643.3608 (C33H56O10P, 0.341 ppm mass tolerance, 60%) (Figure S13). This elemental composition,
though inconclusive, suggested the likelihood that the unknown impurity might be a phospholipid.
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4. Discussion
4.1. Cytotoxicity
The two fractions that were cytotoxic to U937 cells with IC50 values below 100 µg/mL contained
melittin (F-3, IC50 5.4 µg/mL) and (Z)-9-eicosen-1-ol (F-4, IC50 68.8 µg/mL). The latter also contained
trace levels of an unidentified phospholipid. F-1 and F-2 were relatively non-toxic to U937 cells at the
concentrations tested. The former contained mainly low MW amines, such as histamine, dopamine
and noradrenaline, while the latter contained mainly PLA2, a major BV allergen [38,39]. Although
one would have expected fraction F-2 to be cytotoxic due to its PLA2 content, it may be that the
enzymatic activity reduced because of its separation from melittin (i.e., the venom PLA2 and melittin
act synergistically [40]) or as a result of loss of its 3D configuration during the fractionation. Fraction
F-2 also contained variable amounts of the peptides apamin, MCD peptide and secapin, which were
also detected in trace amounts in F-1.
Whereas the cytotoxicity of melittin is generally known in normal human and cancer cells [36,41],
the biological activities of the organic fraction of BV are less well known. Melittin’s cytotoxicity is
thought to be due to membrane-disruption [42] and apoptotic actions mediated via mitochondrial and
caspase activities [43]. During our experiments, the toxicity of F-4 (at 100 µg/mL) was also observed in
adherent normal human fibroblast (HS27) cells in which growth inhibition appeared to be associated
with loss of cell attachment to the cell culture well plate (data not shown). Because of this, it had
been anticipated that with suspended U937 cells, the F-4 fraction would have no such cytotoxic effect
below 100 µg/mL, since adherence was not a prerequisite for cell division and growth. Thus, the
observed toxicity in U937 cells might suggest that F-4 acts within the cell, at least partially, rather than
exclusively externally to it. Its amphiphilic structure would be consistent with an ability to penetrate
and pass through cell membranes.
4.2. Effect on Cytokine Release
The enhancement of LPS-stimulated release of IL-1β in U937 cells was by far the most pronounced
effect induced by all four BV fractions and crude BV, while the effects on TNF-α and IL-6 release
were less marked, with variability between the fractions. The only significant effect on TNF-α release
was due to F-4, while F-2 and F-3, which contained PLA2 and melittin, respectively, were the most
potent enhancers of IL-1β release by the cells following co-stimulation with LPS. Interestingly, F-4
showed anti-IL-6 effects. The IL-1 family of cytokines is closely linked to innate inflammatory and
immune responses more than any other cytokine family, and IL-1β mediates auto-inflammatory
diseases [44]. In the context of bees, the observed several-fold enhancement of IL-1β release by BV
and all of its fractions is thus logical given the defensive function of the venom. Stimulation of IL-6
production is a key target for adjuvants due to its role in promoting B-lymphocyte differentiation
into antibody-producing cells [45–47], T-cell proliferation [48] and development of cell-mediated
cytotoxicity by CD8+ cells [49–51]. Thus, inhibition of IL-6 production by F-4 would suggest
an immuno-suppressive action, but its concomitant stimulatory effect on TNF-α, an important
cytokine involved in the development of resistance to infection and cancer with roles in necrosis
and apoptosis [52], suggests a more subtle mechanism.
Among the major components of F-1, histamine was reported to increase production of IL-6,
expression of histamine receptors, expression of the kinases pp38, pERK and pJNK and induction of
NF-κB in nasal fibroblasts when assayed at 200 µM (~22.2 µg/mL) [14]. This concentration level was
significantly higher than that present in the assay solutions of both the F-1 fraction and BV, which might
explain their non-significant effects on IL-6. Bee venom PLA2, a major allergen and main component
of F-2, and apamin have been shown to possess immune-inducing effects by activating T-cells [17] and
promoting T-cell proliferation [13], respectively. Thus, the effects observed with F-2 on IL-1β and IL-6
production might be related to the effects of both PLA2 and apamin on the cells.
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Additionally, melittin, the sole component of F-3, has been reported to possess adjuvant properties
by enhancing the absorption of intranasal tetanus and diphtheria toxoids [23]. This would support
its effect on IL-1β observed in this study. However, these findings do not suggest that melittin could
reduce the effect of LPS on cells, contrary to some previous studies [26,27]. The concentration used
in the current study (3 µg/mL) was sub-lethal to the U937 cells, but at 10 µg/mL, the concentration
used in a previous study [27], melittin was found in the current study to be 100% cytotoxic. This was
observed previously in dermal fibroblasts, mononuclear cells and fibroblast-like synoviocytes [30]. On
the other hand, the study by Moon et al. [26] assayed both BV and melittin at 0.5–2.0 µg/mL, levels that
are all markedly lower than those employed in the current study. In the same study, LPS was assayed
at 0.5 µg/mL compared to 1.0 µg/mL used in this study, and the cells were initially treated with BV or
melittin for 1 h before treatment with LPS, rather than being simultaneously exposed [26]. Thus, the
differences observed in these in vitro studies in relation to melittin’s role in immuno-modulation might
be related to the different experimental designs and/or concentrations of melittin and LPS used. In
a previous study by Stuhlmeier (2007), neither BV nor melittin was found to inhibit IL-1β-induced
activation of NF-κB. Instead, there were significant increases in the levels of the mRNA of several
pro-inflammatory genes and COX-2 in synoviocytes, dermal fibroblasts and mononuclear cells [30].
The results obtained in our study corroborate these findings.
The main component of F-4, identified in this study as (Z)-9-eicosen-1-ol, resembled the
lipid-soluble compound reported by Pickett et al. (1982) in A. mellifera venom and structurally
elucidated as (Z)-11-eicosen-1-ol [53]. The latter was described as a natural pheromone, which acted
synergistically with amyl acetate, another pheromone produced by the bees [53]. Schmidt et al. (1997)
also reported the same long chain monounsaturated alcohol to be the main component of the oily
fraction of Apis cerana venom [54], a species related to A. mellifera. The compound isolated in F-4 differs
from that previously described with respect to the double bond position, which might be a means of
conveying subtle differences in message recognition among the bees [55].
5. Conclusions
Inflammatory responses mediated by pro-inflammatory cytokines are a key component of
protective immunity against many infections. This study shows that treatment of PMA-differentiated
U937 cells with BV fractions significantly enhances the IL-1β cytokine release effect of LPS in these cells.
However, neither BV nor its fractions could induce any significant cytokine release on their own. The
largest synergistic effect was observed for IL-1β release, which was promoted by all fractions, while
only the lipid fraction, F-4, enhanced TNF-α production in the cells co-stimulated with LPS. Although
fraction F-4, identified to contain (Z)-9-eicosen-1-ol, was stimulatory for IL-1β and TNF-α release, it
produced an inhibitory effect on IL-6 production. The commercial availability of this compound in
larger amounts than can be isolated from the venom will allow us in future work to explore potential
synergies between it and fractions F-1–F-3. In addition, it provides a lead compound for exploring the
effects of other long chain alcohols, since they are accessible via reduction of the wide range of long
chain fatty acids, that is commercially available. Taken together, these results do not support some
studies in the literature that suggest that BV and melittin possess potential anti-inflammatory activity
by antagonising LPS-stimulation of cytokine production. Instead, BV fractions synergise with LPS
in the induction of the IL-1β cytokine release in U937 cells, and the lipophilic fraction has additional
orthogonal effects on TNF-α and IL-6, whereby it induces the former and inhibits the latter. Overall,
these effects provide valuable preliminary information to support further evaluation of purified BV as
a potential source of natural adjuvants for some vaccines.
Supplementary Materials: The following are available online at www.mdpi.com/2076-393X/4/2/11/s1.
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